Literature DB >> 2752104

Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice.

R A Johnson1, T A Waddelow, J Caro, A Oliff, G D Roodman.   

Abstract

The anemia of chronic disease (ACD) is associated with conditions in which macrophage activation occurs. Activated marrow macrophages suppress erythropoiesis in vitro and produce tumor necrosis factor (TNF). Therefore, we tested the effects of chronic in vivo exposure to TNF to determine if it was a candidate for a mediator of ACD. Nude mice were inoculated with Chinese hamster ovary (CHO) cells expressing the human TNF gene or with control cells containing the transfection vector alone. The TNF mice promptly became reticulocytopenic, and after 3 weeks their corrected reticulocytes were 2.6% +/- 0.7% as compared with 7.3% +/- 4% in control mice. The hematocrit at 3 weeks was 28.4% +/- 1.7% in TNF mice as compared with 46% +/- 0.8% in control mice. This anemia was also associated with low serum iron and normal iron stores and increased erythropoietin (Epo) levels. The TNF mice showed an absolute monocytosis with twice the number of circulating monocytes as control mice and had M-colony-stimulating factor (CSF) activity in their serum. The TNF mice also became mildly thrombocytopenic. Marrow CFU-E and BFU-E were profoundly decreased (1.2 +/- 0.2 x 10(3) v 8.6 +/- 0.2 x 10(4) CFU-E per femur, and 6.5 +/- 1 x 10(2) v 8.5 +/- 0.2 x 10(4) BFU-E per femur). Splenic CFU-E and BFU-E were similarly depressed. In contrast, marrow CFU-GM and CFU-GEMM were not affected. The residual BFU-E in TNF mice were relatively resistant to TNF as compared with control mice. These data demonstrate that TNF preferentially inhibits erythropoiesis in vivo and may be important in the pathogenesis of ACD.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2752104

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Thiolated recombinant human tumor necrosis factor-alpha protects against Plasmodium berghei K173-induced experimental cerebral malaria in mice.

Authors:  N S Postma; R C Hermsen; D J Crommelin; W M Eling; J Zuidema
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Distinct clinical and immunologic profiles in severe malarial anemia and cerebral malaria in Zambia.

Authors:  Philip E Thuma; Janneke van Dijk; Rick Bucala; Zufan Debebe; Sergei Nekhai; Thea Kuddo; Mehdi Nouraie; Günter Weiss; Victor R Gordeuk
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

3.  Inhibition of human colony-forming-unit erythroid by tumor necrosis factor requires accessory cells.

Authors:  R T Means; E N Dessypris; S B Krantz
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

4.  Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone.

Authors:  G D Roodman; N Kurihara; Y Ohsaki; A Kukita; D Hosking; A Demulder; J F Smith; F R Singer
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

5.  Mechanisms of erythropoiesis inhibition by malarial pigment and malaria-induced proinflammatory mediators in an in vitro model.

Authors:  Gordon A Awandare; Prakasha Kempaiah; Daniel O Ochiel; Paolo Piazza; Christopher C Keller; Douglas J Perkins
Journal:  Am J Hematol       Date:  2011-02       Impact factor: 10.047

Review 6.  Anemia of inflammation.

Authors:  Elizabeta Nemeth; Tomas Ganz
Journal:  Hematol Oncol Clin North Am       Date:  2014-05-28       Impact factor: 3.722

7.  Cisplatin-associated anemia: an erythropoietin deficiency syndrome.

Authors:  P A Wood; W J Hrushesky
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Inhibition of in vitro erythropoiesis by soluble mediators in Plasmodium chabaudi AS malaria: lack of a major role for interleukin 1, tumor necrosis factor alpha, and gamma interferon.

Authors:  G S Yap; M M Stevenson
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

Review 9.  Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis.

Authors:  F Morceau; M Dicato; M Diederich
Journal:  Mediators Inflamm       Date:  2010-03-01       Impact factor: 4.711

10.  Managing anemia in patients with chronic heart failure: what do we know?

Authors:  Ankur Sandhu; Sandeep Soman; Michael Hudson; Anatole Besarab
Journal:  Vasc Health Risk Manag       Date:  2010-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.